Presented By Raymond Huang at 2014 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Multi trial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse Background:
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Presented By Patrick Wen at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Imaging of bevacizumab treated brain: traditional and emerging concepts Asim K. Bag Joel K Cure Aparna Singhal David Wever Asim K. Bag Joel K Cure Aparna.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.
Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Presented By Christina Tsien at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Presented By Michael Overman at 2016 ASCO Annual Meeting
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Presented By Alan Venook at 2016 ASCO Annual Meeting
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
A cura di Filippo de Marinis
Securing the cure in resectable lung cancer
Presented By Michael Lee at 2016 ASCO Annual Meeting
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Oncol Res Treat 2016;39: DOI: /
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
Improving Survival in Glioblastoma Multiforme
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Baselga J et al. SABCS 2009;Abstract 45.
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
The Road to Quality Improvement in HER2-Positive Breast Cancer
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
Presented By Steven Park at 2016 ASCO Annual Meeting
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Plasma Levels Correlate with Clinical Benefit
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Presented By Andrew Evens at 2016 ASCO Annual Meeting
Fig. 2. HR estimated by the multivariate analysis for predicting factors associated with longer overall survival using a Cox regression model at the time.
Presentation transcript:

Presented By Raymond Huang at 2014 ASCO Annual Meeting Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Background Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Slide 3 Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting RANO Criteria Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting BRAIN trial (AVF3708g) Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Study design Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Response Presented By Raymond Huang at 2014 ASCO Annual Meeting

Inter-reader agreement Presented By Raymond Huang at 2014 ASCO Annual Meeting

Objective Response Rate Presented By Raymond Huang at 2014 ASCO Annual Meeting

Landmark analysis: Objective response versus Survival Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Progression Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Progression Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting PFS: Macdonald vs RANO Presented By Raymond Huang at 2014 ASCO Annual Meeting

Landmark analysis: Progression vs Overall Survival Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Conclusions Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Future directions Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting Acknowledgement Presented By Raymond Huang at 2014 ASCO Annual Meeting